Literature DB >> 25906544

[Combined pulmonary fibrosis and emphysema syndrome].

Marija Alilović, Tatjana Peroš-Golubićić, Jasna Tekavec Trkanjec, Ana Hećimović, Silvana Smojver-Ježek.   

Abstract

CPFE-combined pulmonary fibrosis and emphysema is a new term for a syndrome whose main characteristic is fibrosis in lower pulmonary lobes with simultaneous emphysema in upper pulmonary lobes. CPFE patients have well preserved pulmonary test values for unexpectedly long period, but extremely lowered carbon monoxide diffusion capacity and significant arterial hypertension. All CPFE studies indicate that CPFE occurs predominately in older male population. Smoking is considered main cause in developing CPFE. Reduced survival rate is linked with arterial hypertension extent, and mortality rate is greater than that for patients with isolated pulmonary fibrosis or emphysema. This study is focused on characteristics of twelve CPFE patients. This paper describes cases of 12 patients with the syndrome of pulmonary fibrosis associated with emphysema. All patients were male, mean age of 68 years. At the certain period of life they all were smokers, but most of them were also exposed to air pollution due to their profession. Shortness of breath on exertion was present in all patients. All patients had neat pulmonary function tests with significantly reduced diffusing capacity for carbon mon- oxide (average 39%). Pulmonary arterial hypertension (PAH) averaged 56 mmHg (range 25-75 mmHg) was present in 75% of patients. Four patients died during the period of four months, of which three patients had PAH greater than 70 mmHg. The fourth patient died of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25906544

Source DB:  PubMed          Journal:  Lijec Vjesn        ISSN: 0024-3477


  1 in total

1.  Quantitative CT in mortality prediction in pulmonary fibrosis with or without emphysema.

Authors:  Fatma Üçsular; Gülistan Karadeniz; Gülru Polat; Enver Yalnız; Aysu Ayrancı; Akin Çinkooğlu; Recep Savaş; Hatice Solmaz; Filiz Güldaval; Melih Büyükşirin
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-09-30       Impact factor: 0.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.